<!DOCTYPE html>
<html lang="en">
    <head>
        <meta name="DC.IDENTIFIER" content="http://dx.doi.org/ 10.17917/EHR9-HB86 " scheme="DCTERMS.UI"><title>caNanoLab DOI Landing page</title>
        <style>
            h1 { text-align: center;}
            h2 { text-align: left;}
            table { border: 1px solid #dddddd; text-align: left; padding: 8px }
            td, th { border: 1px solid #dddddd; text-align: left; padding: 8px }
            tr:nth-child(even) { background-color: #dddddd }
        </style>
    </head><body><img src="./assets/images/crdc-logo.svg" alt="CRDC General Commons Logo"><h1> caNanoLab DOI </h1><hr><p><b>Protocol Type:</b> in vitro assay</p><p><b>Protocol Name:</b> NCL Method GTA-3: Hep G2 Hepatocyte Glutathione Assay</p><p><b>Protocol Abbreviation:</b> GTA-3</p><p><b>Protocol Version:</b> 1.2<hr><p><b>DOI:</b> <a href = http://dx.doi.org/ 10.17917/EHR9-HB86 >http://dx.doi.org/ 10.17917/EHR9-HB86 </a></p><p><b>Protocol File:</b> protocols/20240410_18-21-30-922_NCL_Method_GTA-3.pdf<p><b>File Title:</b> GTA-3</p><p><b>Description:</b></b> This protocol describes the analysis of human hepatocarcinoma cells (Hep G2) for reduced and oxidized glutathione, following treatment with nanoparticle formulations, as part of the NCL in vitro preclinical characterization cascade.  A shift from reduced to oxidized glutathione is indicative of oxidative stress, while a decrease in the overall reduced glutathione pool is indicative of conjugative metabolism or impaired synthesis. This protocol utilizes a colorimetric method for glutathione determination.<hr><p><b>Resource Type:</b>  Protocol</p><p><b>Data Access:</b> <a href =https://general.datacommons.cancer.gov/#/data>https://general.datacommons.cancer.gov/#/data</a><p></body></html>